Does elevated DHT indicate increased testosterone-to-DHT conversion activity?

DHT is a principal androgen metabolite of testosterone, particularly relevant to prostate, genital tissues, skin, and hair follicles. The core biochemical claim is established, but interpreting a high blood DHT value as proof of excess 5α-reductase activity is not justified without broader clinical and laboratory context.

Established biology and potency

• 5α-reductase irreversibly converts testosterone to DHT in an NADPH-dependent reaction. Human SRD5A1 and SRD5A2 are the established active isoenzymes; SRD5A1 is broadly distributed (including skin, follicles, liver, and brain), while SRD5A2 is enriched in prostate and male genital tissues.
• DHT generally has greater androgen-receptor potency than testosterone: it has approximately 2–4-fold higher receptor affinity and dissociates more slowly. This commonly permits androgen-receptor signaling at lower concentrations, although maximal signaling and tissue effects are not uniformly greater. For example, prostate bioassays found DHT 2.4-fold more potent for epithelial-mass maintenance but equipotent for apoptosis prevention.

Interpreting elevated DHT

• Increased testosterone-to-DHT conversion is a biologically plausible contributor to elevated serum DHT. Pharmacologic evidence is directionally strong: finasteride lowers serum DHT by roughly 65–70%, and dutasteride by about 94%; modeling estimates SRD5A2 contributes approximately 80% of plasma DHT.
• However, serum DHT is not a direct measure of 5α-reductase activity or DHT exposure in the prostate or scalp. Local production, intracellular retention, and inactivation by 3α/3β-HSDs, AKR1C enzymes, and glucuronidation can uncouple tissue and blood concentrations. Testosterone availability, SHBG, medications/supplements, and clearance also affect serum DHT.

Bottom line

• DHT is produced from testosterone by 5α-reductase and is generally the more potent receptor agonist; a high serum DHT result is compatible with increased conversion but does not specifically demonstrate increased 5α-reductase activity. Confirmation with validated LC-MS/MS and concurrent testosterone, SHBG, LH/FSH, medication, and clinical assessment are needed for meaningful interpretation.